- Home
- WBTN vs CDNA Comparison
WBTN vs CDNA Comparison
Compare WBTN & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WBTN
- CDNA
- Stock Information
- Founded
- WBTN 2005
- CDNA 1998
- Country
- WBTN United States
- CDNA United States
- Employees
- WBTN N/A
- CDNA N/A
- Industry
- WBTN
- CDNA Medical Specialities
- Sector
- WBTN
- CDNA Health Care
- Exchange
- WBTN NYSE
- CDNA Nasdaq
- Market Cap
- WBTN 1.1B
- CDNA 1.0B
- IPO Year
- WBTN 2024
- CDNA 2014
- Fundamental
- Price
- WBTN $9.14
- CDNA $19.21
- Analyst Decision
- WBTN Buy
- CDNA Buy
- Analyst Count
- WBTN 6
- CDNA 6
- Target Price
- WBTN $12.92
- CDNA $30.33
- AVG Volume (30 Days)
- WBTN 275.8K
- CDNA 989.3K
- Earning Date
- WBTN 08-07-2025
- CDNA 07-30-2025
- Dividend Yield
- WBTN N/A
- CDNA N/A
- EPS Growth
- WBTN N/A
- CDNA N/A
- EPS
- WBTN N/A
- CDNA 1.07
- Revenue
- WBTN $1,347,441,000.00
- CDNA $346,421,000.00
- Revenue This Year
- WBTN $9.01
- CDNA $13.31
- Revenue Next Year
- WBTN $14.69
- CDNA $15.46
- P/E Ratio
- WBTN N/A
- CDNA $17.90
- Revenue Growth
- WBTN 3.71
- CDNA 25.92
- 52 Week Low
- WBTN $6.75
- CDNA $14.09
- 52 Week High
- WBTN $24.19
- CDNA $34.84
- Technical
- Relative Strength Index (RSI)
- WBTN N/A
- CDNA 57.48
- Support Level
- WBTN N/A
- CDNA $18.64
- Resistance Level
- WBTN N/A
- CDNA $19.44
- Average True Range (ATR)
- WBTN 0.00
- CDNA 0.75
- MACD
- WBTN 0.00
- CDNA -0.05
- Stochastic Oscillator
- WBTN 0.00
- CDNA 46.86
About WBTN WEBTOON ENTERTAINMENT INC
Webtoon Entertainment Inc is a storytelling platform where a vibrant community of creators and users discover, create and share new content. It has pioneered a cultural movement by revolutionizing the storytelling format and democratizing content creation and publication connecting 24 million creators with approximately 170 million monthly active users in over 150 countries around the world.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.